NewsoncologyMay 17, 2026
Breakthrough Phase 2 Trial Results for Zolbetuximab in Gastric Cancer
The Phase 2 trial of zolbetuximab combined with mFOLFOX6 and nivolumab shows promising results for treating unresectable CLDN18.2-positive gastric cancer. This breakthrough could reshape treatment protocols and investment strategies in oncology.
Dr. Yuki Tanaka
